Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

Patent metadata

Field	Value
Publication number	US-12018067-B2
Application number	US-202318150957-A
Country	US
Kind code	B2
Filing date	Jan 6, 2023
Priority date	Mar 17, 2009
Publication date	Jun 25, 2024
Grant date	Jun 25, 2024

Abstract

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

First claim

What is claimed is:

1. A non-naturally occurring anti-HIV-1 PGG14 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising complementary determining regions having the amino acid sequences of SEQ ID NOS: 113, 114, and 43 and (b) a heavy chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 110, 111, 102, and 103.

2. A non-naturally occurring anti-HIV-1 PGG14 monoclonal antibody or antigen binding portion thereof comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 36 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 35.

3. A non-naturally occurring anti-HIV-1 PGG14 monoclonal antibody or antigen binding portion thereof comprising (a) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO.: 20 and (b) a light chain sequence comprising the amino acid sequence of SEQ ID NO.: 22.

4. A pharmaceutical composition comprising the antibody of any one of claims 1 to 3 and a pharmaceutically acceptable carrier,
wherein the carrier is selected from the group consisting of a buffer, organic acid, antioxidant, preservative, alkyl paraben, oligopeptide, protein, amino acid, hydrophilic polymer, carbohydrate, chelating agent, tonicifier, sugar, and surfactant.

5. The composition according to claim 4 , wherein the buffer is acetate, Tris, phosphate, or citrate.

6. The composition according to claim 4 , wherein the antioxidant is ascorbic acid or methionine.

7. The composition according to claim 4 , wherein the preservative is octadecyldimethylbenzene, ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl alcohol, or benzyl alcohol.

8. The composition according to claim 4 , wherein the alkyl paraben is methyl paraben, propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, or m-cresol.

9. The composition according to claim 4 , wherein the oligopeptide comprises at most ten residues.

10. The composition according to claim 4 , wherein the protein is an immunoglobulin, gelatin, or serum albumin.

11. The composition according to claim 4 , wherein the amino acid is glycine, glutamine, asparagine, histidine, arginine, or lysine.

12. The composition according to claim 4 , wherein the hydrophilic polymer is polyvinylpyrrolidone.

13. The composition according to claim 4 , wherein the carbohydrate is a monosaccharide, disaccharide, dextrin, glucose, or mannose.

14. The composition according to claim 4 , wherein the chelating agent is EDTA.

15. The composition according to claim 4 , wherein the tonicifier is trehalose or sodium chloride.

16. The composition according to claim 4 , wherein the surfactant is polysorbate.

17. The composition according to claim 4 , wherein said composition comprises a lyophilized formulation.

18. The composition according to claim 4 , wherein said composition comprises an aqueous solution.

19. The composition according to claim 4 , wherein the antibody is present at a concentration between 5-200 mg/mL.

20. The composition according to claim 4 , wherein the antibody is present at a concentration between 10-100 mg/mL.

21. The composition according to claim 4 , further comprising at least one therapeutic agent.

22. The composition according to claim 21 , wherein the therapeutic agent is a second antibody.

23. The composition according to claim 21 , wherein the therapeutic agent is an anti-viral agent.

24. The composition according to claim 21 , wherein the therapeutic agent is an anti-infective agent.

25. The composition according to claim 21 , wherein the therapeutic agent is a cardioprotectant.

26. The composition according to claim 21 , wherein the antibody is present at a concentration between 5-200 mg/mL.

27. The composition according to claim 21 , wherein the antibody is present at a concentration between 10-100 mg/mL.

28. The composition according to claim 4 , wherein the antibody is encapsulated in microcapsules.

29. The antibody of any one of claims 1-3 , wherein the antigen is gp120.

Assignees

• Theraclone Sciences Inc
• Int Aids Vaccine Initiative Inc
• Scripps Research Inst

Inventors

• Chan-Hui Po-Ying
• Frey Steven
• Olsen Ole
• Mitcham Jennifer
• Moyle Matthew
• Phogat Sanjay K
• Burton Dennis R
• Walker Laura Marjorie
• Poignard Pascal Raymond Georges
• Koff Wayne
• Simek-Lemos Melissa Danielle De Jean De St Marcel
• Kaminsky Stephen

Classifications

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K16/114 Primary

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• A61K39/21

  Retroviridae, e.g. equine infectious anemia virus · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title